Bartosz Chmielowski MD PhD

Oncology•Los Angeles, CA

Hematologic Oncology, Melanoma, Sarcoma

Associate Professor, Medicine, UCLA School of Medicine

Join to View Full Profile

100 UCLA Medical PlazaSuite 550Los Angeles, CA 90095
Phone+1 310-794-4955
Fax+1 310-794-4955

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Medical College of GeorgiaResidency, Internal Medicine, 2001 - 2005
Wroclaw Medical UniversityClass of 1995

Certifications & Licensure

CA State Medical License 2004 - 2026
GA State Medical License 2004 - 2005
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012

Clinical Trials

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2007 Apr 01
Completed
Phase 2
A Phase I/II Study of Daily Oral Dosing With Temozolomide and Sunitinib Malate for 6 Weeks of an 8-Week Cycle in Patients With Metastatic and Unresectable Locally-Advanced Malignant Melanoma Start of enrollment: 2009 Apr 01
Study of Gene Modified Immune Cells in Patients With Advanced Melanoma Start of enrollment: 2009 Oct 13
Completed
Phase 2
Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma Start of enrollment: 2008 Dec 01
Completed
Phase 1
A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma Start of enrollment: 2011 Feb 01
Completed
Phase 2
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Start of enrollment: 2013 Jul 01
Terminated
Phase 1, Phase 2
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Start of enrollment: 2014 Jan 01
Completed
Phase 3
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma Start of enrollment: 2014 Jul 23
Completed
Phase 2
Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Start of enrollment: 2019 Jun 28
RECRUITING
PHASE1, PHASE2
Join now to see all

Publications & Presentations

PubMed

Longitudinal Genomic Analysis to Fine-Tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients With BRAF V600-Mutant Metastatic Melanoma.
Reinhard Dummer, Shahneen Sandhu, Wilson H Miller, Marcus O Butler, Matthew H Taylor
Clinical Cancer Research. 2025-03-19
2 citations
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC...
Yvonne M Mowery, Karla V Ballman, Angela M Hong, Scott M Schuetze, Andrew J Wagner
Lancet. 2024-11-23
2 citations
The landscape of drug sensitivity and resistance in sarcoma.
Ahmad Al Shihabi, Peyton J Tebon, Huyen Thi Lam Nguyen, Jomjit Chantharasamee, Sara Sartini
Cell Stem Cell. 2024-10-03

Press Mentions

ASCO 2022 | Ascentage Pharma Releases Updated Results Demonstrating the Therapeutic Potential of Alrizomadlin (APG-115) plus Pembrolizumab in Patients with Solid Tumors Who Progressed on ImmunotherapiesJune 7th, 2022
Reversing Resistance to PD-1 Inhibitors with Combination Immunotherapy in Patients with Advanced MelanomaApril 8th, 2022
Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021September 13th, 2021
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Other Languages

Polish